Today we shared positive topline data from our PIVOT-006 Phase 3 clinical trial in intermediate-risk non-muscle invasive #bladdercancer.
PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm.
Learn more: bit.ly/4iUtgWe
PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm.
Learn more: bit.ly/4iUtgWe
0:57